دورية أكاديمية
Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints.
| العنوان: | Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints. |
|---|---|
| المؤلفون: | Isler B; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia.; Infection Management Services, Princess Alexandra Hospital, Brisbane, Australia., Vatansever C; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Özer B; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Çınar G; Infectious Diseases and Clinical Microbiology, School of Medicine, Ankara University Ankara, Turkey., Aslan AT; Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Falconer C; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia., Bauer MJ; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia., Forde B; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia., Şimşek F; Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, Istanbul, Turkey., Tülek N; Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Atilim University, Ankara, Turkey., Demirkaya H; Infectious Diseases and Clinical Microbiology, Ankara Hospital, Başkent University, Ankara, Turkey., Menekşe Ş; Infectious Diseases, Koşuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey., Akalin H; Infectious Diseases and Clinical Microbiology, School of Medicine, Uludağ University, Bursa, Turkey., Balkan İİ; Infectious Diseases and Clinical Microbiology, School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Aydın M; Infectious Diseases and Clinical Microbiology, Ümraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Tigen ET; Infectious Diseases and Clinical Microbiology, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey., Demir SK; Infectious Diseases and Clinical Microbiology, Demiroglu Bilim University, Istanbul, Turkey., Kapmaz M; Infectious Diseases and Clinical Microbiology, Koç University Hospital, Istanbul, Turkey., Keske Ş; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey.; Infectious Diseases, VKV American Hospital, Istanbul, Turkey., Doğan Ö; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Arabacı Ç; Clinical Microbiology, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, University of Health Sciences, Istanbul, Turkey., Yağcı S; Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey., Hazırolan G; Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Bakır VO; Graduate School of Sciences and Engineering, Koç University, Istanbul, Turkey., Gönen M; Industrial Engineering, College of Engineering, Koç University, Istanbul, Turkey., Saltoğlu N; Infectious Diseases and Clinical Microbiology, School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Azap A; Infectious Diseases and Clinical Microbiology, School of Medicine, Ankara University Ankara, Turkey., Azap Ö; Infectious Diseases and Clinical Microbiology, Ankara Hospital, Başkent University, Ankara, Turkey., Akova M; Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Ergönül Ö; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey.; Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, Turkey., Can F; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey.; Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, Turkey., Paterson DL; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia., Harris PNA; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia. |
| المصدر: | Infectious diseases (London, England) [Infect Dis (Lond)] 2023 Sep; Vol. 55 (9), pp. 607-613. Date of Electronic Publication: 2023 Jun 30. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101650235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2374-4243 (Electronic) Linking ISSN: 23744243 NLM ISO Abbreviation: Infect Dis (Lond) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London, England : Informa Healthcare, [2015]- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents*/pharmacology , Klebsiella*/genetics, Humans ; Cephalosporins/pharmacology ; Microbial Sensitivity Tests ; Cefiderocol |
| مستخلص: | Background: Cefiderocol is generally active against carbapenem-resistant Klebsiella spp. (CRK) with higher MICs against metallo-beta-lactamase producers. There is a variation in cefiderocol interpretive criteria determined by EUCAST and CLSI. Our objective was to test CRK isolates against cefiderocol and compare cefiderocol susceptibilities using EUCAST and CLSI interpretive criteria. Methods: A unique collection ( n = 254) of mainly OXA-48-like- or NDM-producing CRK bloodstream isolates were tested against cefiderocol with disc diffusion (Mast Diagnostics, UK). Beta-lactam resistance genes and multilocus sequence types were identified using bioinformatics analyses on complete bacterial genomes. Results: Median cefiderocol inhibition zone diameter was 24 mm (interquartile range [IQR] 24-26 mm) for all isolates and 18 mm (IQR 15-21 mm) for NDM producers. We observed significant variability between cefiderocol susceptibilities using EUCAST and CLSI breakpoints, such that 26% and 2% of all isolates, and 81% and 12% of the NDM producers were resistant to cefiderocol using EUCAST and CLSI interpretive criteria, respectively. Conclusions: Cefiderocol resistance rates among NDM producers are high using EUCAST criteria. Breakpoint variability may have significant implications on patient outcomes. Until more clinical outcome data are available, we suggest using EUCAST interpretive criteria for cefiderocol susceptibility testing. |
| فهرسة مساهمة: | Keywords: CLSI; Cefiderocol; EUCAST; Klebsiella; NDM; bloodstream |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Cephalosporins) |
| تواريخ الأحداث: | Date Created: 20230701 Date Completed: 20230710 Latest Revision: 20231213 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/23744235.2023.2226709 |
| PMID: | 37391868 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 2374-4243 |
|---|---|
| DOI: | 10.1080/23744235.2023.2226709 |